These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29884904)

  • 1. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
    Boudreaux SP; Duren RP; Call SG; Nguyen L; Freire PR; Narayanan P; Redell MS; Conneely OM
    Leukemia; 2019 Jan; 33(1):52-63. PubMed ID: 29884904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells.
    Duren RP; Boudreaux SP; Conneely OM
    PLoS One; 2016; 11(3):e0150450. PubMed ID: 26938745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms.
    Wenzl K; Troppan K; Neumeister P; Deutsch AJ
    Curr Drug Targets; 2015; 16(1):38-46. PubMed ID: 25410408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Z-Ligustilide Selectively Targets AML by Restoring Nuclear Receptors Nur77 and NOR-1-mediated Apoptosis and Differentiation.
    Wang C; Liu G; Dou G; Yang Y; Chen L; Ma H; Jiang Z; Ma H; Li C; Li L; Jiang M; Lu Q; Li P; Qi H
    Phytomedicine; 2021 Feb; 82():153448. PubMed ID: 33421904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.
    Ramirez-Herrick AM; Mullican SE; Sheehan AM; Conneely OM
    Blood; 2011 Mar; 117(9):2681-90. PubMed ID: 21205929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
    Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
    Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
    Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
    Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
    Tarighat SS; Santhanam R; Frankhouser D; Radomska HS; Lai H; Anghelina M; Wang H; Huang X; Alinari L; Walker A; Caligiuri MA; Croce CM; Li L; Garzon R; Li C; Baiocchi RA; Marcucci G
    Leukemia; 2016 Apr; 30(4):789-99. PubMed ID: 26536822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
    Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
    Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
    J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
    Ding H; Vincelette ND; McGehee CD; Kohorst MA; Koh BD; Venkatachalam A; Meng XW; Schneider PA; Flatten KS; Peterson KL; Correia C; Lee SH; Patnaik M; Webster JA; Ghiaur G; Smith BD; Karp JE; Pratz KW; Li H; Karnitz LM; Kaufmann SH
    Cancer Res; 2021 May; 81(10):2666-2678. PubMed ID: 33414171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
    Pulikkottil AJ; Bamezai S; Ammer T; Mohr F; Feder K; Vegi NM; Mandal T; Kohlhofer U; Quintanilla-Martinez L; Sinha A; Buske C; Rawat VPS
    Leukemia; 2022 Feb; 36(2):416-425. PubMed ID: 34462525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia.
    Boudreaux SP; Ramirez-Herrick AM; Duren RP; Conneely OM
    Oncogenesis; 2012 Jul; 1(7):e19. PubMed ID: 23552735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity.
    Wu L; Amarachintha S; Xu J; Oley F; Du W
    Br J Haematol; 2018 Nov; 183(3):445-456. PubMed ID: 30106181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.